This segment focuses on the development, manufacturing, and commercialization of rapid, point-of-care screening and testing products. These tests are designed to provide quick and accurate results for various health conditions, including those related to wellness and potential diseases. Research and development activities include the continuous improvement of existing tests and the development of new tests to address emerging health needs. Technologies and methodologies employed include lateral flow assays and other rapid diagnostic techniques. The patient impact is significant, as these tests enable faster diagnosis and treatment decisions. Market positioning is based on providing convenient and cost-effective testing solutions. Future opportunities include expanding the product portfolio and entering new markets. Regulatory aspects involve obtaining necessary approvals from relevant authorities. Partnerships and collaborations are crucial for distribution and market access.

This segment is dedicated to the research, development, and potential commercialization of a vaccine candidate against SARS-CoV-2. Research and development activities include preclinical studies, clinical trials, and manufacturing processes. The company utilizes advanced biotechnology and immunology to develop effective vaccines. The therapeutic area is infectious diseases, specifically targeting the COVID-19 pandemic. The patient impact is substantial, as a successful vaccine could prevent infection and reduce the severity of the disease. Market positioning is based on addressing a critical unmet medical need. Future opportunities include expanding the vaccine pipeline and exploring partnerships for manufacturing and distribution. Regulatory aspects involve obtaining necessary approvals from regulatory bodies. Collaborations with research institutions and other pharmaceutical companies are essential for accelerating vaccine development and market access.